Cytotoxic T cells react to cardiac peptides in patients with cancer that receive immunotherapy, resulting in myocarditis. Identifying the targets for T cells in patients who are immunosuppressed will enable a better understanding of individual risk before treatment is initiated
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Johnson, D. B. et al. Nat. Rev. Clin. Oncol. 19, 254–267 (2022).
Wang, D. Y. et al. JAMA Oncol. 4, 1721–1728 (2018).
Axelrod, M. L. et al. Nature 611, 818–826 (2022).
Ribas, A. & Wolchok, D. J. Science 359, 1350–1355 (2018).
Wei, S. C. et al. Cancer Discov. 11, 614–625 (2021).
Johnson, D. B. et al. New Engl. J. Med. 375, 1749–1755 (2016).
Caforio, A. L. P. et al. Int. J. Cardiol. 179, 166–177 (2015).
Myers, J. M. et al. JCI Insight 1, e85851 (2016).
Gil-Cruz, C. et al. Science 366, 881–886 (2019).
Lv, H. et al. J. Clin. Invest. 121, 1561–1573 (2011).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wong, A., Epelman, S. Unchecked autoreactive CD8+ T cells wreak havoc in cancer immunotherapy. Nat Cardiovasc Res 1, 1111–1113 (2022). https://doi.org/10.1038/s44161-022-00184-9
Published:
Issue Date:
DOI: https://doi.org/10.1038/s44161-022-00184-9